Cloud-Clone pitches CBA kits as a way to turn standard flow cytometers into multiplex protein tools

Cloud-Clone Corp. says its Cytometric Bead Array kits let labs use existing flow cytometers for high-plex protein testing instead of buying dedicated multiplex systems. The company is targeting a global installed base it estimates at 150,000 to 200,000 instruments, with a new 36-plex panel and compatibility across major brands.

Why it matters: - Cloud-Clone is positioning CBA kits as a lower-cost alternative to dedicated multiplex detection platforms. - The approach is aimed at labs that already own flow cytometers but face bottlenecks from limited access to specialized multiplex instruments. - The company says the model reduces the need for outsourced testing, repeated sample splitting and new capital equipment purchases.

What happened: - Cloud-Clone Corp. introduced its Cytometric Bead Array technology as a way to run multiplex protein assays on standard laboratory flow cytometers. - The release was dated September 1, 2026, from Huston, Texas. - Cloud-Clone also announced a 36-plex neuro-endocrine-immune panel built on the same platform. - The company included a product page for more information: Cloud-Clone official website.

The details: - CBA technology uses fluor-encoded microspheres coated with capture antibodies for different analytes. - Mixed beads are incubated with samples to form bead-target-detection antibody complexes. - A flow cytometer identifies analytes through APC-based bead coding and reads protein levels through PE fluorescence intensity. - Cloud-Clone says the kits work on Beckman Coulter DxFLEX and CytoFLEX series, BD FACSMelody and FACSCanto series, Agilent NovoCyte series and Thermo Fisher Attune NxT. - The assays run on entry-level analytical through high-end sorting flow cytometers if APC and PE channels are available. - The APC-Cy7 channel is required for panels with more than 27 analytes. - The company says the assays need only 25 μL of sample volume. - Cloud-Clone says the assays reach pg/mL sensitivity and a dynamic range of 3 to 5 orders of magnitude. - The company says most samples do not need serial dilution retesting. - The 36-plex panel combines RAAS hormones ALD and AngII, cardiac markers ANP and BNP, sympathetic mediators EPI and NE, vascular endothelial factor EDN1 and Th1/Th2/Th17 cytokines in one reaction vessel. - Cloud-Clone says its assay components are produced in-house, including fluor-encoded microspheres and matched capture-detection antibody pairs. - The company says its antibody library exceeds 27,000 clones. - Each panel undergoes cross-reactivity testing, matrix-effect characterization and spike-recovery validation. - Typical spike recovery is 80% to 120%, with R² of at least 0.97, according to the release.

Between the lines: - The release is framed as an instrument-agnostic pitch for labs that already have flow cytometry hardware but not dedicated bead-array platforms. - Cloud-Clone is trying to turn a common cell-analysis instrument into a broader protein-quantification workflow, which could widen access to multiplex testing if performance holds up in practice. - The company also leans on supply-chain resilience, arguing that in-house component production reduces exposure to disruptions. - Cloud-Clone says major suppliers Beckman Coulter, BD, Agilent and Thermo Fisher Scientific held about 78.3% of the global flow-cytometry market in 2023, underscoring the size of the installed base it is targeting. - The company estimates global flow cytometer inventory at 150,000 to 200,000 units and says more than 23,000 new units shipped in 2025.

What's next: - Cloud-Clone says it will keep expanding its CBA panel portfolio and optimizing assay performance. - The company says it will continue supporting research into immune, cardiovascular, neuroendocrine and inflammatory disease mechanisms. - Researchers considering the platform will need compatible lasers and detection channels before running higher-plex panels.